MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: www.youtube.com/msviewsandnews -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~


Thursday, April 16, 2009

Rebif is the only self-administered DMD proven in all three key efficacy measures of relapsing MS

Rebif is proven to delay disability progression
  • In a 2-year study, Rebif 44 mcg tiw significantly reduced the number of patients with disability progression* at 2 years (26% vs 37% with placebo; P=0.01)[1]

Patients with sustained disability progression* at 2 years (%)
Patients with sustained disability progression* at 2 years (%)
Adapted from Rebif US Prescribing Information.[1]
* Progression is defined as an increase of 1 point for EDSS <5.5 and 0.5 points for
EDSS ≥5.5.
Results from the Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis (PRISMS) study.[2]
For full study design and description, click here.

Rebif significantly reduces clinical relapse rate

  • Over 2 years, patients taking Rebif 44 mcg tiw had significantly fewer relapses than patients on placebo (annualized relapse rate: 0.87 vs 1.28; P<0.0001)[2]
  • Significantly more patients were relapse-free at 2 years with Rebif 44 mcg tiw (32% vs 15% with placebo; P<0.0001)[1]

Median time to first relapse
Median time to first relapse
Adapted from Rebif US Prescribing Information.[1]
Results from the Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis (PRISMS) study.[2]
For full study design and description, click here.

  • Rebif 44 mcg tiw also significantly increased the median time to second relapse (median not reached over 2 years of treatment vs 15 months with placebo; P<0.0001)[2]

Rebif significantly reduces MRI lesion activity

  • Rebif 44 mcg tiw delivered an 84% reduction in gadolinium-enhancing lesions at 9 months (1.3 vs 8.0 with placebo; P<0.001)[3]
  • Based on a subgroup of 134 patients from the PRISMS study who received 11 consecutive monthly PD/T2 and Gd-enhanced/T1-weighted (Gd-T1) MRI scans beginning 1 month before treatment initiation
  • At 2 years, Rebif 44 mcg tiw showed a 78% reduction in T2 active lesions as compared with placebo (P<0.0001)[2]

The exact correlation between MRI findings and the current or future clinical status of patients, including disability progression, is unknown.

* Progression is defined as an increase of 1 point for EDSS <5.5 and 0.5 points for
EDSS ≥5.5.


.
Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================

No comments: